NCT05368831View on ClinicalTrials.gov

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

September 7, 2022

Study Completion Date

September 7, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

NST-1024

Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam

Trial Locations (1)

Unknown

Labcorp Clinical Research Unit Ltd., Leeds

Sponsors
All Listed Sponsors
lead

NorthSea Therapeutics B.V.

INDUSTRY